Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF) Supplemental Material Index Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nochi, T. Articles by Kiyono, H. Search for Related Content PubMed PubMed Citation Articles by Nochi, T. Articles by Kiyono, H. Related Collections Related Article Social Bookmarking                      What's this?

¹ Division of Mucosal Immunology, ² Division of Virology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan
³ Core Research for Evolutional Science and Technology, Japan Science and Technology Corporation, Saitama 332-0012, Japan
⁴ Laboratory of Veterinary Epidemiology, Department of Veterinary Science, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka 599-8531, Japan

CORRESPONDENCE Hiroshi Kiyono: kiyono{at}ims.u-tokyo.ac.jp

Mucosally ingested and inhaled antigens are taken up by membranous or microfold cells (M cells) in the follicle-associated epithelium of Peyer's patches or nasopharynx-associated lymphoid tissue. We established a novel M cell–specific monoclonal antibody (mAb NKM 16–2-4) as a carrier for M cell–targeted mucosal vaccine. mAb NKM 16–2-4 also reacted with the recently discovered villous M cells, but not with epithelial cells or goblet cells. Oral administration of tetanus toxoid (TT)– or botulinum toxoid (BT)–conjugated NKM 16–2-4, together with the mucosal adjuvant cholera toxin, induced high-level, antigen-specific serum immunoglobulin (Ig) G and mucosal IgA responses. In addition, an oral vaccine formulation of BT-conjugated NKM 16–2-4 induced protective immunity against lethal challenge with botulinum toxin. An epitope analysis of NKM 16–2-4 revealed specificity to an (1,2)-fucose–containing carbohydrate moiety, and reactivity was enhanced under sialic acid–lacking conditions. This suggests that NKM 16–2-4 distinguishes (1,2)-fucosylated M cells from goblet cells containing abundant sialic acids neighboring the (1,2) fucose moiety and from non-(1,2)-fucosylated epithelial cells. The use of NKM 16–2-4 to target vaccine antigens to the M cell–specific carbohydrate moiety is a new strategy for developing highly effective mucosal vaccines.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

• Terahara, K., Yoshida, M., Igarashi, O., Nochi, T., Pontes, G. S., Hase, K., Ohno, H., Kurokawa, S., Mejima, M., Takayama, N., Yuki, Y., Lowe, A. W., Kiyono, H. (2008). Comprehensive Gene Expression Profiling of Peyer's Patch M Cells, Villous M-Like Cells, and Intestinal Epithelial Cells. J. Immunol. 180: 7840-7846 [Abstract] [Full Text]  
• Nochi, T., Yuki, Y., Matsumura, A., Mejima, M., Terahara, K., Kim, D.-Y., Fukuyama, S., Iwatsuki-Horimoto, K., Kawaoka, Y., Kohda, T., Kozaki, S., Igarashi, O., Kiyono, H. (2007). A novel M cell specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J. Cell Biol. 179: i8-i8 [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS